Myelosuppression clinical trials

Explore recruiting myelosuppression clinical trials.

Recruiting myelosuppression studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myelosuppression trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018

Germany, Austria, Netherlands, Poland, Belgium, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer

Czechia, Poland, Sweden, Spain, Netherlands, Germany +4 more

Therapeutic use (Phase IV) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy

Bulgaria, Poland, Belgium, Germany, Spain, Austria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

COMBOLA Trial: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A multicenter, open-label, randomized, phase II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogeneic hematopoietic stem cell transplantation treated with decidua stromal cells (DSC) or best available treatment (BAT)

Sweden, Norway, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Myelosuppression trials by city

Myelosuppression in Toronto Myelosuppression in Vancouver Myelosuppression in Montreal Myelosuppression in Calgary Myelosuppression in Edmonton Myelosuppression in Ottawa Myelosuppression in Winnipeg Myelosuppression in Quebec City Myelosuppression in Hamilton Myelosuppression in Kitchener Myelosuppression in London Myelosuppression in Halifax Myelosuppression in New York Myelosuppression in Los Angeles Myelosuppression in Chicago Myelosuppression in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease